: Schwab’s stock rises as November client assets rise 12% from year-ago period
Charles Schwab Corp.’s stock SCHW rose by 2.4% in premarket trading on Thursday after the financial firm said total client assets rose 12% in November...
: U.S. stocks open higher, with Dow rising after record close
U.S. stocks opened higher on Thursday, attempting a sixth straight day of gains, as investors digested fresh economic data on stronger-than-expected retail sales and a...
: Berkshire Hathaway ups its Occidental Petroleum stake by nearly $600M
Berkshire Hathaway Inc. BRK.ABRK.B, the conglomerate controlled by billionaire Warren Buffett, acquired about10.5 million shares of Occidental Petroleum Corp. OXY stock valued at nearly $589...
: Apellis Pharmaceuticals’ stock slides 14% after company gets negative trend vote for eye treatment in Europe
Apellis Pharmaceuticals Inc.’s stock APLS tumbled 14% early Thursday, after the company said it’s been informed of a negative trend vote on the European marketing...
: Mesa Air delays earnings update by up to 15-days
Mesa Air Group, Inc. MESA said Thursday it plans to file a notification of a late filing for its annual report for the fiscal year...
: MindMed announces positive results in trial of LSD as a treatment for generalized anxiety disorder
Mind Medicine Inc. MNMD said Thursday a Phase 2 trial testing LSD as a treatment for generalized anxiety disorder met its main goal, showing a...
: Steel maker Nucor expects fourth-quarter profit to drop from the previous quarter on lower pricing and reduced volumes
Nucor Corp. NUE said Thursday it expects to report fourth-quarter earnings ranging from $2.75 a share to $2.85 a share. Analysts are estimating earnings of...
: Alaska Air sees Q4 capacity and revenue at high end of guidance amid strong holiday travel demand
Alaska Air Group Inc. ALK said Thursday it expects fourth-quarter capacity and revenue to come in at the high end of guidance, boosted by strong...
: Moderna’s stock rallies 7.9% after announcing positive data in trial of melanoma treatment combined with Merck’s Keytruda
Moderna Inc.’s stock MRNA soared 7% early Thursday, after the biotech and partner Merck MRK announced positive data from a mid-stage trial of Moderna’s mRNA-4157...